DECN Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume80.00K
Average Volume (3M)N/A
Market Cap
$380.00
Enterprise Value$2.44M
Total Cash (Recent Filing)$210.85K
Total Debt (Recent Filing)$3.24M
Price to Earnings (P/E)―
Beta71.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding380,486,150
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)9.92
Price to Sales (P/S)2.42
P/FCF Ratio-3.42
Enterprise Value/Market Cap6.42K
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit5.28
Enterprise Value/Ebitda-1.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DECN FAQ
What was Decision Diagnostics Corp’s price range in the past 12 months?
Currently, no data Available
What is Decision Diagnostics Corp’s market cap?
Decision Diagnostics Corp’s market cap is $380.00.
When is Decision Diagnostics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decision Diagnostics Corp’s earnings last quarter?
Currently, no data Available
Is Decision Diagnostics Corp overvalued?
According to Wall Street analysts Decision Diagnostics Corp’s price is currently Overvalued.
Does Decision Diagnostics Corp pay dividends?
Decision Diagnostics Corp does not currently pay dividends.
What is Decision Diagnostics Corp’s EPS estimate?
Decision Diagnostics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decision Diagnostics Corp have?
Decision Diagnostics Corp has 380,486,150 shares outstanding.
What happened to Decision Diagnostics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decision Diagnostics Corp?
Currently, no hedge funds are holding shares in DECN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decision Diagnostics Corp
Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
PharmaCyte Biotech
―
Enveric Biosciences
―
Bluejay Diagnostics
―
SciSparc Ltd.
―
Virax Biolabs Group Ltd. Class A
―